Agios Pharm (AGIO)
Agios Pharmaceuticals, Inc. is a Nasdaq-listed biopharmaceutical company focused on cellular metabolism. The company develops medicines for rare and serious blood disorders, with PYRUKYND (mitapivat) as its lead product. PYRUKYND is approved for the treatment of hemolytic anemias in adults with pyruvate kinase deficiency, and Agios is also studying it in other settings, including sickle cell disease and pediatric PK deficiency. Another product, AQVESME, is being developed for adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. Agios also has a pipeline that includes tebapivat, AG-181, and AG-236, which target indications such as lower-risk myelodysplastic syndrome, phenylketonuria, and polycythemia vera. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-AGIO
|
$45.76
|
23.7% Upside
|
Undervalued
|
$42.63
|
15.2% Upside
|
Fair
|
Good
|
—
|
—
|
—
|
0.0%
|
July 30, 2026
|
-5.4x
|
2.0x
|
34.4x
|
2.382 B
|
1.263 B
|
1.5%
|
84.2%
|
17.6
|
—
|
91.0%
|
